Innate Pharma Presents Preliminary P-II (TELLOMAK) Trial Results of Lacutamab for the Treatment of Advanced Mycosis Fungoides
Shots:
- The company reported the preliminary results from an ongoing P-II (TELLOMAK) trial that evaluates lacutamab in patients with mycosis fungoides who express KIR3DL2 & were prior treated with two lines of systemic therapy
- As of the data cutoff of Mar 2022, patients in the KIR3DL2-expressing MF patients (cohort 2) & non-expressing cohort (cohort 3), received a median of 4 & 4.5 prior systemic therapies & had a median follow-up of 12.2mos. & 13.8mos.; ORR (28.6% & 11.1%); m-PFS (12.0mos. & 8.5mos.); PFS @12mos. (53.6% & 39.6%)
- The clinical responses & favorable safety profile were observed in the P-II (TELLOMAK) study along with the skin responses, grade ≥3 Treatment-related TEAEs (5.1%), AEs leading to patients discontinuation (2.6%)
Ref: Innate Pharma | Image: Innate Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
